GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Scaled Net Operating Assets

Oruka Therapeutics (FRA:HQ1) Scaled Net Operating Assets : (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oruka Therapeutics's operating assets for the quarter that ended in Mar. 2024 was € Mil. Oruka Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was € Mil. Oruka Therapeutics's Total Assets for the quarter that ended in . 20 was € Mil. Therefore, Oruka Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was .

Oruka Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Oruka Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Scaled Net Operating Assets Chart

Oruka Therapeutics Annual Data
Trend Dec24
Scaled Net Operating Assets
0.02

Oruka Therapeutics Semi-Annual Data
Mar24
Scaled Net Operating Assets -0.35

Competitive Comparison of Oruka Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Oruka Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Scaled Net Operating Assets falls into.


Oruka Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oruka Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: . 20 )
=(-)/
=

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

Oruka Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: . 20 )
=(-)/
=

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Scaled Net Operating Assets
Comparable Companies
ATXS ATAI GLUE PHAT PRME AURA OLMA ALDX ERAS CYDY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ORKA:USA HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines